A research team has published a randomized clinical trial demonstrating for the first time that a multidisciplinary approach integrating specific physiotherapy and cognitive-behavioral therapy is effective in improving the symptoms and physical aspects of the quality of life of patients with functional movement disorders.
Clinical trial finds multidisciplinary approach improves quality of life for movement disorder patients retrieved 12 October 2024 from https://medicalxpress.com/news/2024-10-clinical-trial-multidisciplinary-approach-quality.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Oct 11, 2024 Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Long-term metastatic melanoma survival dramatically improves on immunotherapy, clinical trial findsLong-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues.
Read more »
Clinical trial: Preventing heart injury caused by anticancer drugsThe RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) used to prevent the cardiotoxic effects of anthracycline-based chemotherapy in patients with lymphoma.
Read more »
High-dose vitamin D3 does not provide benefit for metastatic colorectal cancer, clinical trial showsSOLARIS (Alliance A021703), a multicenter, double-blind, randomized Phase III clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition of high-dose vitamin D3 to standard treatment for patients with untreated metastatic colorectal cancer.
Read more »
Researchers announce clinical trial results for hard-to-treat breast and bladder cancersProfessors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's Presidential Symposium to over 30,000 attendees at the European Society for Medical Oncology (ESMO) Congress 2024.
Read more »
Team publishes results from clinical trial evaluating cabozantinib in advanced neuroendocrine tumorsThe Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET (A021602), a phase III trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET)...
Read more »
Clinical trial demonstrates success in treating rare blood disorderA clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than one in 5,000 people worldwide.
Read more »